SecBot SecBot
8-K ·Filed Feb 26, 2026

VCEL

Vericel Corp
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago SEC0001628280-26-012003
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong revenue growth, margin expansion, and raised guidance suggest continued market penetration of MACI. Traders should monitor the commercial manufacturing ramp-up in the new Burlington facility and progress on the UK MHRA application as potential future catalysts.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$37.68
T+0 close · Feb 26, 2026 · via day close
Latest settled
−6.71%
T+60 · $35.15
Vs SPY
−14.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $37.68entry
  2. T+1 · 9mo ago −5.31%α −4.86% · $35.68
  3. T+5 · 9mo ago −9.77%α −8.64% · $34.00
  4. T+20 · 8mo ago −18.21%α −11.80% · $30.82
  5. T+60 · 6mo ago −6.71%α −14.46% · $35.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vericel Corp reported strong Q4 and full-year 2025 financial results with total revenue of $276.3 million, driven by 21% growth in MACI revenue. The company achieved a 59% increase in net income to $16.5 million and raised its 2026 revenue guidance to $316-$326 million, signaling continued momentum in its advanced therapies business.

Key Financial Metrics

Revenue
$276.3M
+16.0% YoY
EPS
$0.32
Guidance
$316M-$326M
raised
Gross Margin
74%

Key Facts

  • Q4 2025 revenue grew 23% YoY to $92.9 million
  • Full-year 2025 revenue reached $276.3 million, up 16% from 2024
  • MACI revenue grew 21% to $239.5 million for the year
  • Net income increased 59% to $16.5 million for the year
  • 2026 revenue guidance raised to $316-$326 million
  • Record Q4 gross margin of 79% and adjusted EBITDA margin of 40%

Financial Impact

Revenue growth of 16% and net income growth of 59% in 2025 with 2026 revenue guidance suggesting 14-18% growth

revenueepsnet incomemarginsguidance

Segment Breakdown

SegmentRevenueGrowth
MACI$239.5M+21.0%
Burn Care$36.8MNot reported

Risk Factors

  • Increased operating expenses due to new facility costs could pressure margins
  • Dependence on MACI revenue growth (87% of total revenue)
  • Regulatory risks with UK MHRA application

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-012003
Document: vcel-20260226.htm0001628280-26-012003
Document: 0001628280-26-012003-index-headers.html0001628280-26-012003
Document: 0001628280-26-012003-index.html0001628280-26-012003
Document: 0001628280-26-012003.txt0001628280-26-012003

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026